DAVID GRAHAM to Tetracycline
This is a "connection" page, showing publications DAVID GRAHAM has written about Tetracycline.
Connection Strength
2.746
-
Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance. Aliment Pharmacol Ther. 2001 Apr; 15(4):513-8.
Score: 0.180
-
Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
Score: 0.177
-
Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000 Nov; 44(11):3203-5.
Score: 0.175
-
Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera? or Lactobacillus reuteri for treatment na?ve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter. 2019 Dec; 24(6):e12659.
Score: 0.162
-
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. Aliment Pharmacol Ther. 1999 Feb; 13(2):169-72.
Score: 0.155
-
Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
Score: 0.144
-
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Oct; 11(5):935-8.
Score: 0.141
-
Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2017 06; 63(2):77-79.
Score: 0.134
-
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep; 44(3):537-63.
Score: 0.121
-
Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol. 1995 Mar; 90(3):403-5.
Score: 0.118
-
Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol. 1994 Aug; 89(8):1203-5.
Score: 0.113
-
Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1994 Apr; 8(2):259-62.
Score: 0.111
-
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol. 1993 Nov; 28(11):939-42.
Score: 0.108
-
Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993 Feb; 7(1):111-3.
Score: 0.102
-
Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012 Oct; 17(5):382-90.
Score: 0.098
-
Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb; 102(2):493-6.
Score: 0.095
-
Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991 Aug 15; 115(4):266-9.
Score: 0.092
-
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter. 2011 Aug; 16(4):295-300.
Score: 0.092
-
Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
Score: 0.059
-
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
Score: 0.056
-
The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials. Gastroenterology. 2003 Aug; 125(2):639; author reply 640-1.
Score: 0.053
-
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother. 2001 Apr; 47(4):459-61.
Score: 0.045
-
Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000 Jun; 14(6):745-50.
Score: 0.042
-
Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000 Feb; 14(2):211-5.
Score: 0.042
-
Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999 Jun; 4(2):106-12.
Score: 0.040
-
Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing. Scand J Gastroenterol. 1993 Aug; 28(8):690-4.
Score: 0.026
-
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992 May 01; 116(9):705-8.
Score: 0.024
-
Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol. 1990 Apr; 85(4):394-8.
Score: 0.021
-
Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002 Apr; 97(4):857-60.
Score: 0.012
-
Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997 Nov; 108(5):504-9.
Score: 0.009